Vivani Medical, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivani Medical, Inc. (VANI) on November 20, 2023. The report discloses a material event regarding the departure of a named executive officer within the company's wholly-owned subsidiary, Cortigent, Inc.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed relates to severance compensation:
- Severance Payment: Approximately $70,000.
- Benefits: Reimbursement of COBRA coverage premiums for up to six months, subject to eligibility and election.
Material Changes
The primary material change reported is the termination without cause of Scott Dunbar, a named executive officer and former Acting CEO of the company's predecessor, Second Sight Medical Products, Inc. This termination occurred as part of a broader reduction in workforce at Cortigent, Inc., effective November 20, 2023.
Outlook, Risks, and Management Commentary
Management intends to execute a customary separation and release agreement with Mr. Dunbar to formalize the severance terms. The filing notes that the full text of the Separation Agreement will be filed as an exhibit to the company's Annual Report on Form 10-K. No specific guidance, forward-looking financial outlook, or new risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the final terms of the Separation Agreement once filed as an exhibit to the Form 10-K.
- Monitor subsequent filings for details on the scope of the workforce reduction at Cortigent, Inc.
- Confirm the appointment of a new Acting CEO or leadership structure for the Cortigent subsidiary.
- Review upcoming quarterly reports for the impact of this executive departure on operational strategy.